EMA and FDA Align on Good AI Practice in Drug Development
The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have jointly issued guiding principles aimed at ensuring the safe and responsible use of AI throughout the medicines life cycle. This initiative is designed to harmonize processes for drug developers utilizing AI-driven programs to foster innovation that ultimately benefits patients.
Joint Publication of Guiding Principles
On January 14, 2026, the EMA and FDA released a comprehensive document titled Guiding Principles of Good AI Practice in Drug Development. This document outlines a shared regulatory vision for the application of artificial intelligence across all phases of drug development.
The collaborative effort between these two regulatory bodies aims to harness the potential of AI to accelerate the journey from innovation to the delivery of safe and effective medicines, while simultaneously ensuring patient safety and maintaining rigorous data and regulatory standards.
Scope and Core Concepts
The Principles provide high-level guidance for various stakeholders including drug developers, marketing authorization applicants, and holders on how AI should be employed to generate and monitor evidence throughout all stages of the medicines life cycle. This encompasses everything from early research and clinical development to manufacturing and post-marketing safety activities.
Key concepts emphasized in the Principles include:
- Alignment with ethical and human-centric values
- Adherence to relevant drug development standards
- Risk-based approach
- Clear context of use
- Robust data governance
- Multidisciplinary expertise
- Life cycle management
- Accessible communication about AI systems
Examples of applications for these Principles include:
- AI-enabled clinical trial design and patient recruitment
- Machine-learning-driven pharmacovigilance and signal detection
- Analysis of real-world evidence to support regulatory and post-authorization decision-making
- Predictive AI tools for manufacturing process control and quality assurance
Impact on International Cooperation
This joint publication marks a significant milestone in the renewed cooperation between the EU and U.S. in the realm of emerging health technologies. By establishing a common set of expectations at an early stage, the EMA and FDA seek to promote international harmonization, encourage innovation, and minimize regulatory fragmentation.
For companies currently using or planning to implement AI technologies, it is advisable to evaluate their existing practices against the newly established Principles. While the adoption of these Principles is currently voluntary, early alignment could offer a strategic advantage, potentially influencing future regulatory standards on both sides of the Atlantic.
